DE112011102355T5 - Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes - Google Patents

Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes Download PDF

Info

Publication number
DE112011102355T5
DE112011102355T5 DE112011102355T DE112011102355T DE112011102355T5 DE 112011102355 T5 DE112011102355 T5 DE 112011102355T5 DE 112011102355 T DE112011102355 T DE 112011102355T DE 112011102355 T DE112011102355 T DE 112011102355T DE 112011102355 T5 DE112011102355 T5 DE 112011102355T5
Authority
DE
Germany
Prior art keywords
antibody
activated
potentiated form
seq
potentiated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE112011102355T
Other languages
German (de)
English (en)
Inventor
Anmelder Gleich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44863147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE112011102355(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010129293/15A external-priority patent/RU2500427C2/ru
Priority claimed from RU2011124809/15A external-priority patent/RU2532323C2/ru
Application filed by Individual filed Critical Individual
Publication of DE112011102355T5 publication Critical patent/DE112011102355T5/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE112011102355T 2010-07-15 2011-07-15 Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes Withdrawn DE112011102355T5 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2010129293/15A RU2500427C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
RU2010129293 2010-07-15
RU2011124809/15A RU2532323C2 (ru) 2011-06-20 2011-06-20 Лекарственное средство для лечения патологического синдрома и способ лечения функциональных нарушений кишечника
RU2011124809 2011-06-20
PCT/IB2011/002178 WO2012007839A2 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Publications (1)

Publication Number Publication Date
DE112011102355T5 true DE112011102355T5 (de) 2013-04-25

Family

ID=44863147

Family Applications (1)

Application Number Title Priority Date Filing Date
DE112011102355T Withdrawn DE112011102355T5 (de) 2010-07-15 2011-07-15 Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes

Country Status (24)

Country Link
US (1) US8637030B2 (enExample)
EP (1) EP2593138A2 (enExample)
JP (2) JP2013532181A (enExample)
KR (1) KR101901465B1 (enExample)
CN (1) CN103096927A (enExample)
AR (1) AR082245A1 (enExample)
AU (1) AU2011278032B2 (enExample)
BR (1) BR112013000842A2 (enExample)
CA (1) CA2804964C (enExample)
CL (1) CL2013000097A1 (enExample)
DE (1) DE112011102355T5 (enExample)
EA (1) EA030542B1 (enExample)
ES (1) ES2425004R1 (enExample)
FR (1) FR2962651A1 (enExample)
GB (1) GB2496794B (enExample)
IL (1) IL224215A (enExample)
IT (1) ITTO20110628A1 (enExample)
MX (1) MX2013000542A (enExample)
MY (1) MY157564A (enExample)
NZ (1) NZ606765A (enExample)
PE (1) PE20130397A1 (enExample)
PH (1) PH12013500108A1 (enExample)
SG (1) SG187035A1 (enExample)
WO (1) WO2012007839A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2012017324A2 (en) 2010-07-15 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
NZ606775A (en) * 2010-07-15 2015-08-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating genitourinary system disorders
PH12013500107A1 (en) 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
CA2805091A1 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions comprising a homopathically potentized form of an antibody to human cannabinoid receptor
PH12013500144A1 (en) 2010-07-21 2018-03-21 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
JP2013533269A (ja) 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
CN106349388B (zh) 2015-07-17 2021-04-02 上海佳文英莉生物技术有限公司 一种促细胞程序性坏死抗体及其应用
CN207908510U (zh) 2016-09-21 2018-09-25 维布兰特公司 安装在抽水马桶上的传感器
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
FI4021505T3 (fi) * 2019-08-29 2024-03-01 Oleg Iliich Epshtein Lääke tartuntatautien hoitamiseksi
EP4624487A1 (en) * 2022-11-24 2025-10-01 Tokushima University Production of antibodies against protein
WO2025144085A1 (ru) * 2023-12-25 2025-07-03 Леонид Владимирович КОСМОДЕМЬЯНСКИЙ Способ лечения боли

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2197266C1 (ru) 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation
US7572441B2 (en) 2002-08-02 2009-08-11 Oleg Iliich Epshtein Media and method for treating pathological syndrome
US7582294B2 (en) 2002-08-02 2009-09-01 Oleg Oliich Epshtein Medicament for treating prostate diseases

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4987127A (en) 1989-01-31 1991-01-22 Dal Sirany Method of treating a virus outbreak
SU1730144A1 (ru) 1989-02-24 1992-04-30 Научный Центр По Разработке И Внедрению Современных Методов Молекулярной Диагностики Способ подавлени репродукции вирусов
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
RU2007989C1 (ru) 1991-11-12 1994-02-28 Акционерное общество "Трейдис" Способ габович подбора гомеопатических препаратов и их разовой дозы
US5741488A (en) 1992-10-08 1998-04-21 The Kennedy Institute For Rheumatology Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
DK140992D0 (da) 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5879677A (en) 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
RU2033784C1 (ru) 1993-05-28 1995-04-30 Индивидуальное частное предприятие "Диалог" Устройство для репродуцирования гомеопатических и изопатических препаратов
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US5629286A (en) 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
IL110035A0 (en) 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
RU2137483C1 (ru) 1995-08-02 1999-09-20 Божедомов Владимир Александрович Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции
EP0884042A4 (en) 1996-02-12 2006-01-04 Oleg Iliich Epshtein MEDICAMENT AND METHOD FOR TREATING AN ORGANISM WITH THIS
AU2576697A (en) 1996-04-19 1997-11-12 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient
IL118096A0 (en) 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
RU2114605C1 (ru) 1996-09-30 1998-07-10 Олег Ильич Эпштейн Защитная добавка для косметических средств
RU2114646C1 (ru) 1996-09-30 1998-07-10 Олег Ильич Эпштейн Способ повышения защитных свойств организма при воздействии внешних физических факторов
RU2132181C1 (ru) 1996-09-30 1999-06-27 Эпштейн Олег Ильич Средство для воздействия на организм
RU2099052C1 (ru) 1996-12-26 1997-12-20 Тамара Михайловна Воробьева Лекарственное средство для восстановления психофизиологического гомеостаза, нарушенного вследствие употребления алкоголя
RU2103999C1 (ru) 1997-01-31 1998-02-10 Олег Ильич Эпштейн Способ лечения алкоголизма
RU2104006C1 (ru) 1997-02-14 1998-02-10 Олег Ильич Эпштейн Способ лечения наркомании
RU2104032C1 (ru) 1997-03-11 1998-02-10 Общество с ограниченной ответственностью "Снежный барс" Способ усиления лечебного эффекта лекарственных средств
DE19746868A1 (de) 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
RU2122858C1 (ru) 1997-12-29 1998-12-10 Яковлева Людмила Борисовна Гомеопатическое лекарственное средство седативного действия "вернисон"
RU2187334C2 (ru) 1998-05-22 2002-08-20 Эпштейн Олег Ильич Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
RU2161955C1 (ru) 1999-07-16 2001-01-20 Эпштейн Олег Ильич Способ изменения физико-химических или физико-химических и биологических свойств вещества
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2177795C1 (ru) 2001-02-15 2002-01-10 Эпштей Олег Ильич Гомеопатическое лекарственное средство для лечения и профилактики аденовирусных инфекций у детей
RU2192882C1 (ru) 2001-04-18 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
WO2003037372A1 (en) 2001-10-31 2003-05-08 Oleg Iliich Epshtein Method for restoring disordered physiological processes and a medicament for carrying out said method
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2001134982A (ru) 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
RU2205026C1 (ru) 2002-03-15 2003-05-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2197266C1 (ru) 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
US7572441B2 (en) 2002-08-02 2009-08-11 Oleg Iliich Epshtein Media and method for treating pathological syndrome
US7582294B2 (en) 2002-08-02 2009-09-01 Oleg Oliich Epshtein Medicament for treating prostate diseases
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"Animal models in biological psychiatry" Hrsg. Kalueff A.V. N-Y, "Nova Science Publishers, Inc.", 2006, S. 137-152
"Hum. Antibodies. Monoclonal and recombinant Antibodies, 30 years after" von Laffly E., Sodoyer R. - 2005 - Bd. 14. - N 1-2. S. 33-55
Bristol scale of stool form: Guidance for Industry Irritable Bowel Syndrome - Clinical Evaluation of Products for Treatment. U.S. Department of Health and Human Services, Food and Drug Administration; Center for Drug Evaluation and Research (CDER) - März 2010.
Castagne V. et al., Antibodies to S100 Proteins haue anxiolytic-like activity at ultralos doses in the adult rat, J Pharm Pharmacol. 2008, 60(3): 309-16
Coopman, G. P., Kennis, H. M., Two Methods to Assess the gastrointestinal transit-time in mice//Z. Vershuchstierk, Bd. 19, Nr. 5, S. 298-303, 1977
CPMP/EWP/785/97, 2003, Points to Consider an the Evaluation of Medicinal Products for 483 the Treatment of Irritable Bowel Syndrome, London, zugänglich unter: 484 http://www.emea.europa.eu/pdfs/human/ewp/078597en.pdf.
Epstein O. I., Antibodies to calcium-binding S100B Protein block the conditioning of long-term sensitization in the terrestrial snail, Pharmacol Biochem Behav., 2009, 94(1): 37-42
Immunotechniques, G. Frimel, M., "Meditsyna", 1987, S. 9-33
Labus, S. Jennifer, et al. The Central Role of Gastrointestinal-Specific Anxiety in Irritable Bowel Syndrome: Further Validation of the Visceral Sensitivity Index. Psychomotor Medicine, 2007; 69: 89-98.
Muller-Lissner, S., Koch, G., Talley, N. J., et al., 2004, Subject's Global Assessment of Relief: An Appropriate Method to Assess the Impact of Treatment an IBS-Related Symptoms in Clinical Trials, J Clin. Epidemiol, 56: 310-316
Senticar J., Da Re P., 3-methyl-6-(N-diethyl-amino-methyl)-Flavone-a new smooth muscle relaxant//Arzneimittel-Forsch, Nr. 9, S. 653-697 (1959)
Snaith, R. Philip. The Hospital Anxiety and Depression Scale. Health and Quality of Life Outcomes 2003, 1: 1-4, http://www.hqlo.com/content/1/1/29.
V. Schwabe "Homeopathic medicines", M., 1967, S. 14-29
Visuelle Analogskala - Reizdarmsyndrom (VAS-IBS): Guidance for Industry Irritable Bowel Syndrome - Clinical Evaluation of Products for Treatment. U.S. Department of Health and Human Services, Food and Drug Administration; Center for Drug Evaluation and Research (CDER) - März 2010
Voronina T. A. et al., Kapitel 8. Antibodies to S-100 Protein in anxiety-depressive disorders in experimental and clinical conditions
Yardan et al., Usefulness of S100B Protein in Neurological Disorders, J Pak Med Assoc Bd. 61, Nr. 3, März 2011

Also Published As

Publication number Publication date
ES2425004R1 (es) 2014-07-09
FR2962651A1 (fr) 2012-01-20
SG187035A1 (en) 2013-02-28
US8637030B2 (en) 2014-01-28
CN103096927A (zh) 2013-05-08
US20130004574A1 (en) 2013-01-03
WO2012007839A3 (en) 2012-04-26
ES2425004A2 (es) 2013-10-10
GB2496794B (en) 2017-11-01
WO2012007839A2 (en) 2012-01-19
KR20130060264A (ko) 2013-06-07
GB2496794A (en) 2013-05-22
NZ606765A (en) 2015-08-28
AU2011278032A1 (en) 2013-03-07
ITTO20110628A1 (it) 2012-01-16
EA030542B1 (ru) 2018-08-31
CL2013000097A1 (es) 2015-01-09
CA2804964A1 (en) 2012-01-19
KR101901465B1 (ko) 2018-09-21
IL224215A (en) 2016-03-31
MX2013000542A (es) 2013-06-28
AR082245A1 (es) 2012-11-21
MY157564A (en) 2016-06-30
EA201300125A1 (ru) 2013-12-30
BR112013000842A2 (pt) 2016-06-07
AU2011278032B2 (en) 2015-07-23
PE20130397A1 (es) 2013-04-10
JP2013532181A (ja) 2013-08-15
GB201302654D0 (en) 2013-04-03
CA2804964C (en) 2016-06-28
EP2593138A2 (en) 2013-05-22
PH12013500108A1 (en) 2017-01-06
JP2016210787A (ja) 2016-12-15

Similar Documents

Publication Publication Date Title
DE112011102355T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes
EP0804236B1 (de) Verwendung von anti-tnf-antiköpern als arzneimittel zur behandlung von erkrankungen mit einem erhöhten interleukin-6 serumspiegel
DE112011102362T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen
DE112011102350T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems
DE112011102349T5 (de) Pharmazeutische Zusammensetzung und Behandlungsverfahren
DE112011102411T5 (de) Verfahren zur Behandlung von Aufmerksamkeits-Mangel-Hyperaktivitäts-Störung
DE112011102409T5 (de) Verfahren zur Behandlung der Alzheimer-Krankheit
DE112011102638T5 (de) Pharmazeutische Zusammensetzung und Verfahren zur Behandlung und Prävention der Krankheiten, die durch HIV verursacht werden oder mit HIV zusammenhängen
DE112011102640T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung undPrävention von Infektionskrankheiten
CN109071645A (zh) 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
DE112011102397T5 (de) Pharmazeutische Kombinationszusammensetzungen und Verfahren zur Behandlung von Schwindel, Kinetose und vegetativ-vaskulärer Dystonie
DE112011102356T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit dem Herz-Kreislauf-System in Verbindung stehen
DE112011102412T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von mit Atemwegserkrankungen bzw. Atemwegsleiden assoziierten Erkrankungen bzw. Leiden
DE112011102649T5 (de) Medikament und Verfahren zur Prävention einer HIV-Kontamination, Prävention und Behandlung von Krankheiten, die durch HIV verursacht werden, und von mit HIV zusammenhängen-den Krankheiten, einschließlich AIDS
DE112011102358T5 (de) Verfahren zur Erhöhung der Wirkung einer aktivierten-potenzierten Form eines Antikörpers
DE112011102639T5 (de) Pharmazeutische Zusammensetzung und Verfahren zur Hemmung der Erzeugung oder zur Verstärkung der Eliminierung von P24-Protein
WO2012136534A2 (de) Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten
DE102011006781A1 (de) Antikörperprodukt, umfassend n spezifische Antikörper
RU2500427C2 (ru) Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
RU2532323C2 (ru) Лекарственное средство для лечения патологического синдрома и способ лечения функциональных нарушений кишечника
DE4409513C1 (de) Verwendung von anti-TNF-Antikörpern als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
DE202013011988U1 (de) Entzündungshemmende Rezeptur

Legal Events

Date Code Title Description
R012 Request for examination validly filed

Effective date: 20140513

R082 Change of representative

Representative=s name: DF-MP DOERRIES FRANK-MOLNIA & POHLMAN PATENTAN, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee